Strategic proposals for predicting drug-drug interactions during new drug development: Based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs

Journal of Toxicological Sciences

Volumn 21, Issue 5, 1996, Pages 299-300

  Watabe, Tadashi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; FLUOROURACIL; PRODRUG; SORIVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DRUG FATALITY; DRUG POTENTIATION; DRUG SCREENING; NONHUMAN; PREDICTION; RAT; TOXICITY TESTING;

EID: 0030512057     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.21.5_299     Document Type: Conference Paper

References (2)

1. Nishimoto, T, Yokoyama, N., Sakamoto, H., Ohata, K., Kohno, S., Murai, K., and Tatsumi, H. Studies on the metabolic fate of Brovavir (YN-72) II; metabolism in rats. Iyakuhin Kenkyu 21, 378-389 (1990).
2. Desgranges, C., Razaka, G., Clercq, E. D., Herdewijn, P., Balzarini, J., Drouillet, F., and Bricaud, H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 46, 1094-1101 (1986).